Actos Reaps Benefits Of Avandia Cardiac Risk Publicity
Executive Summary
The publicity surrounding the emerging cardiovascular safety signal for GlaxoSmithKline's Avandia is providing a boost for the only other marketed thiazolidinedione, Takeda's Actos
You may also be interested in...
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials